An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
Video content above is prompted by the following question(s):
WVE-N531 Shows Promising Efficacy in DMD at Interim FORWARD-53 Analysis
September 26th 2024In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Read More
Cycling Training Shows Protective Effects on Gait, Balance in DMD
August 22nd 2024Both cycling and home-based exercise training helped maintain gait and balance parameters in children with Duchenne muscular dystrophy (DMD), with cycling training also improving antero-posterior balance.
Read More